Findings from an 856-patient analysis suggest that evaluating GA topography beyond foveal involvement may better capture patient-reported functional impairment. Anegondi and colleagues analyzed ...
Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients. Swissmedic, the Swiss Agency for Therapeutic Products, has ...
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Murdock about how the rise of "Ozempic face" has placed aesthetic injectables at the ...
Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions. A new study 1 from Poland published in the Journal ...
For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD ...
The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). NovaBridge Biosciences ...
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Zacks about ONL1204, a first-in-class Fas pathway inhibitor showing promise in ...
The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026. STAAR Surgical has announced that ...
Priyanka Sanghi, BSc, MSc, MBBS, highlights how fundus autofluorescence and optical coherence tomography may help uncover long-term retinal footprints invisible to standard examination.
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME. This ...
A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...
Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results